Developing as a promising advance in the battle against obesity, this medication is attracting considerable attention . It combines effects of two established GLP-1 binding agonists, liraglutide, with an new glucose-dependent incretin component. Initial study results have shown substantial body reduction in patients with obesity , potentially o… Read More